The US Food and Drug Administration (FDA) has approved the first drug in the world that can treat cancer from its source and origin, for adults and children. Virrakvi depends on genetic mutation treatment of cancer tumors, regardless of the type or location of the disease.
"Certification of release and the introduction of this drug is an important step in the treatment of cancer, because it treats it from its source and treats the genes of cancerous tumors, regardless of their original location in the human body," said Scott Gottlieb, US Agency commissioner.
Gottlieb stressed that this new drug will help cancer patients get the right treatment. Viratave contributes to the treatment of people with different cancers, but they have a common genetic mutation.
"Traditionally, cancer has been treated on the basis of cancer sources, but now treatment will be carried out anywhere in the body because you treat the original genes that cause tumors," said David Hayman, president of the Early Drug Development Center at the Sloan Kettering Mimoreal Cancer Center in New York.
The drug was tested in humans and a child recovered within a few months after taking the drug. The drug will be given to two bodies, the first in tablets or capsules, and the other in the form of drugs for children.